CS444985A2 - Method of substituted imidazo-(1,5-a)pyridine derivatives production - Google Patents

Method of substituted imidazo-(1,5-a)pyridine derivatives production

Info

Publication number
CS444985A2
CS444985A2 CS854449A CS444985A CS444985A2 CS 444985 A2 CS444985 A2 CS 444985A2 CS 854449 A CS854449 A CS 854449A CS 444985 A CS444985 A CS 444985A CS 444985 A2 CS444985 A2 CS 444985A2
Authority
CS
Czechoslovakia
Prior art keywords
alkyl
pyridine derivatives
formula
substituted imidazo
stereoisomers
Prior art date
Application number
CS854449A
Other languages
English (en)
Other versions
CS268672B2 (en
Inventor
Leslie J Dr Browne
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Priority to CS868019A priority Critical patent/CS268685B2/cs
Priority to CS868018A priority patent/CS268684B2/cs
Priority to CS868021A priority patent/CS268687B2/cs
Priority to CS868022A priority patent/CS268688B2/cs
Priority to CS868020A priority patent/CS268686B2/cs
Publication of CS444985A2 publication Critical patent/CS444985A2/cs
Publication of CS268672B2 publication Critical patent/CS268672B2/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CS854449A 1984-06-20 1985-06-18 Method of substituted imidazo-(1,5-a)pyridine derivatives production CS268672B2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CS868019A CS268685B2 (en) 1984-06-20 1986-11-05 Method of substituted imidazopyrrole,-pyridine and-azepine derivatives production
CS868018A CS268684B2 (en) 1984-06-20 1986-11-05 Method of substituted imidazopyrrole,-pyridine and-azepine derivatives production
CS868021A CS268687B2 (en) 1984-06-20 1986-11-05 Method of substituted imidazopyridine derivatives production
CS868022A CS268688B2 (en) 1985-06-18 1986-11-05 Method of substituted imidazopyrrole,-pyridine and-azepine derivatives production
CS868020A CS268686B2 (en) 1985-06-18 1986-11-05 Method of substituted imidazopyrrole,-pyridine and-azepine derivatives production

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/622,421 US4617307A (en) 1984-06-20 1984-06-20 Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors

Publications (2)

Publication Number Publication Date
CS444985A2 true CS444985A2 (en) 1989-07-12
CS268672B2 CS268672B2 (en) 1990-04-11

Family

ID=24494112

Family Applications (1)

Application Number Title Priority Date Filing Date
CS854449A CS268672B2 (en) 1984-06-20 1985-06-18 Method of substituted imidazo-(1,5-a)pyridine derivatives production

Country Status (31)

Country Link
US (1) US4617307A (cs)
EP (1) EP0165904B1 (cs)
JP (1) JPS6112688A (cs)
KR (1) KR900008566B1 (cs)
AT (1) ATE62415T1 (cs)
AU (1) AU589565B2 (cs)
BG (7) BG60262B2 (cs)
CA (1) CA1276633C (cs)
CS (1) CS268672B2 (cs)
CY (1) CY1750A (cs)
DD (1) DD237510A5 (cs)
DE (1) DE3582452D1 (cs)
DK (1) DK170302B1 (cs)
DZ (1) DZ799A1 (cs)
ES (6) ES8702406A1 (cs)
FI (1) FI80694C (cs)
GR (1) GR851487B (cs)
HK (1) HK23494A (cs)
HU (1) HU202529B (cs)
IE (1) IE58070B1 (cs)
IL (1) IL75546A (cs)
MA (1) MA20459A1 (cs)
MX (1) MX9203369A (cs)
NO (1) NO162467C (cs)
NZ (1) NZ212483A (cs)
PH (1) PH23390A (cs)
PL (6) PL145087B1 (cs)
PT (1) PT80661B (cs)
RO (1) RO92583A (cs)
SU (6) SU1433413A3 (cs)
ZA (1) ZA854615B (cs)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428160A (en) * 1982-12-21 1995-06-27 Ciba-Geigy Corporation Substituted imidazo[5-a]pyridine derviatives and other substituted bicyclic derivatives
US4728645A (en) * 1982-12-21 1988-03-01 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives and other substituted bicyclic derivatives, useful as aromatase inhibitors
US4889861A (en) * 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
GB8510541D0 (en) * 1985-04-25 1985-05-30 Wyeth John & Brother Ltd Heterocyclic compounds
US5171858A (en) * 1985-06-05 1992-12-15 Schering A.G. Preparation of certain 5,6-dihydro-8-phenyl-imidazo[1,5-a]pyridines
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
US4937250A (en) * 1988-03-07 1990-06-26 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
US4749713A (en) * 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
US4797411A (en) * 1986-07-18 1989-01-10 Farmitalia Carlo Erba S.P.A. Cycloalkyl-substituted 4-pyridyl derivatives and use as aromatase inhibitors
GB8820730D0 (en) * 1988-09-02 1988-10-05 Erba Carlo Spa Substituted 5 6 7 8-tetrahydroimidazo/1.5-a/pyridines & process for their preparation
US5057521A (en) * 1988-10-26 1991-10-15 Ciba-Geigy Corporation Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism
CA2026792A1 (en) * 1989-11-01 1991-05-02 Michael N. Greco (6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1h-benzotriazole derivatives
US5066656A (en) * 1989-11-01 1991-11-19 Janssen Pharmaceutica N.V. Pharmacologically active (6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives
MTP1076B (en) * 1990-01-12 1991-09-30 Ciba Geigy Ag Hemihydrate
US5162337A (en) * 1990-10-05 1992-11-10 Merck & Co., Inc. Animal growth promotion
CA2066369A1 (en) * 1991-04-19 1992-10-20 Alex Elbrecht Control of sex differentiation in fish
CH683151A5 (de) * 1991-04-24 1994-01-31 Ciba Geigy Ag Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus.
JPH05176659A (ja) * 1991-04-26 1993-07-20 Merck & Co Inc 家禽における雌性表現型を転換するために抗ミュラー管ホルモンを単独またはアロマターゼ阻害剤と組合せて使用する方法
WO1995028156A1 (en) * 1994-04-14 1995-10-26 Sepracor, Inc. Treating estrogen-dependent diseases with (-)-fadrozole
CA2150326A1 (en) * 1994-05-27 1995-11-28 Kimihiro Murakami Azolyl methyl phenyl derivatives having aromatase inhibitory activity
DE4432106A1 (de) * 1994-09-09 1996-03-14 Hoechst Ag Mit Heterocyclen-N-Oxid-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum, sie enthaltendes Medikament sowie Zwischenprodukte zu ihrer Herstellung
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
CA2494345C (en) * 2002-07-30 2011-11-29 Novartis Ag Combination of an aromatase inhibitor with a bisphosphonate
BR0313293A (pt) * 2002-08-07 2005-06-14 Novartis Ag Compostos orgânicos
WO2004046145A1 (en) * 2002-11-18 2004-06-03 Novartis Ag Imidazo[1, 5a]pyridine derivatives and methods for treating aldosterone mediated diseases
WO2005007627A1 (ja) * 2003-07-18 2005-01-27 Nihon Nohyaku Co., Ltd. フェニルピリジン誘導体、その中間体及びこれを有効成分とする除草剤
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
JP2007529459A (ja) 2004-03-17 2007-10-25 ノバルティス アクチエンゲゼルシャフト 治療に置けるレニン阻害剤の使用
CA2568165A1 (en) * 2004-05-28 2005-12-15 Speedel Experimenta Ag Heterocyclic compounds and their use as aldosterone synthase inhibitors
AR049126A1 (es) * 2004-05-28 2006-06-28 Speedel Experimenta Ag Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing.
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
AU2007267793A1 (en) * 2006-05-26 2007-12-06 Novartis Ag Aldosterone synthase and/or 11beta-hydroxylase inhibitors
JP5042311B2 (ja) 2006-07-20 2012-10-03 ノバルティス アーゲー Ｃｅｔｐ阻害剤としてのアミノピペリジン誘導体
AU2007290695A1 (en) * 2006-08-25 2008-03-06 Novartis Ag Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase
EP2120938A4 (en) * 2006-12-20 2010-12-08 Merck Sharp & Dohme IMIDAZOPYRIDINE ANALOGUE AS CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES
HRP20120476T1 (hr) 2007-11-05 2012-06-30 Novartis Ag Derivati 4-benzilamino-1-karboksiacil-piperidina kao cetp inhibitori korisni za liječenje bolesti kao što su hiperlipidemija ili arterioskleroza
PL2229356T3 (pl) 2007-12-03 2012-03-30 Novartis Ag 1,2-Dipodstawione pochodne 4-benzyloamino-pirolidyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic
EP2095819A1 (en) * 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
KR101442897B1 (ko) 2009-05-28 2014-09-23 노파르티스 아게 네프릴리신 억제제로서의 치환된 아미노프로피온산 유도체
CA2763565A1 (en) 2009-05-28 2010-12-02 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
AR086665A1 (es) * 2011-06-14 2014-01-15 Lilly Co Eli Inhibidor de aldosterona sintasa y composiciones farmaceuticas
BR112014000333A2 (pt) 2011-07-08 2017-02-07 Novartis Ag método de tratamento de aterosclerose em sujeitos com triglicerídeo alto
CA2863339C (en) 2012-01-17 2021-03-23 Novartis Ag Forms and salts of a dihydropyrrolo[1,2-c]imidazolyl aldosterone synthase or aromatase inhibitor
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
HRP20180958T1 (hr) 2013-02-14 2018-07-27 Novartis Ag Supstituirani derivati bisfenolbutanfosfonske kiseline kao inhibitori za nep (neutralnu endopeptidazu)
MX2016001021A (es) 2013-07-25 2016-08-03 Novartis Ag Bioconjugados de polipeptidos de apelina sinteticos.
CN105612172A (zh) 2013-07-25 2016-05-25 诺华股份有限公司 用于治疗心力衰竭的环状多肽
US9931372B2 (en) 2015-01-23 2018-04-03 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
PL3250555T3 (pl) * 2015-01-29 2021-08-02 Recordati Ag Sposób wytwarzania skondensowanych pochodnych imidazolu
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
JP2016074729A (ja) * 2015-12-31 2016-05-12 国立大学法人 千葉大学 イミダゾリウム塩及びそれを用いた不斉合成触媒並びにイミダゾリウム塩の製造方法
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
WO2018078049A1 (en) 2016-10-27 2018-05-03 Damian Pharma Ag Aldosterone synthase inhibitor
BR112019007954A2 (pt) * 2016-10-27 2019-07-02 Damian Pharma Ag inibidor da aldosterona sintase
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
BR112020022173A2 (pt) 2018-05-03 2021-02-02 Damian Pharma Ag r-fadrozol para uso no tratamento de aldostonerismo
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
US20230089867A1 (en) 2018-11-27 2023-03-23 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
WO2020110011A1 (en) 2018-11-27 2020-06-04 Novartis Ag Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5124517B1 (cs) * 1971-03-15 1976-07-24
FR2449689A1 (fr) * 1979-02-20 1980-09-19 Logeais Labor Jacques Nouveaux derives condenses de pyrrolidine ou de piperidine, leur procede de preparation et leurs applications en therapeutique
GB2101595B (en) * 1981-06-22 1985-05-30 Ciba Geigy Ag Substituted imidazo(1,5-a)pyridines, process for their manufacture, pharmaceutical preparations containing these compounds and their therapeutic application
US4444775A (en) * 1981-06-22 1984-04-24 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridines
US4361567A (en) * 1981-10-05 1982-11-30 Schering Corporation Treatment of peptic ulcer disease
US4409226A (en) * 1981-10-05 1983-10-11 Schering Corporation Imidazo[1,5-a]pyridines
US4588732A (en) * 1982-12-21 1986-05-13 Ciba-Geigy Corporation Certain imidazo(1,5-a)pyridine derivatives and their use as thromboxane synthetase inhibitors
US4470986A (en) * 1982-12-21 1984-09-11 Ciba-Geigy Corporation Certain imidazo (1,5-A) pyridine aliphatic carboxylic acid derivatives and their use as selective thromboxane inhibitors

Also Published As

Publication number Publication date
HUT37936A (en) 1986-03-28
CA1276633C (en) 1990-11-20
ES555539A0 (es) 1988-04-01
PL145087B1 (en) 1988-08-31
FI852399L (fi) 1985-12-21
JPS6112688A (ja) 1986-01-21
BG60352B2 (bg) 1994-11-30
BG60306B2 (bg) 1994-07-25
PL145814B1 (en) 1988-11-30
ES8802048A1 (es) 1988-03-16
SU1443802A3 (ru) 1988-12-07
ES8800681A1 (es) 1987-11-16
NO852474L (no) 1985-12-23
BG60353B2 (bg) 1994-11-30
FI80694B (fi) 1990-03-30
EP0165904B1 (de) 1991-04-10
NO162467C (no) 1990-01-10
FI852399A0 (fi) 1985-06-17
FI80694C (fi) 1990-07-10
ES8802155A1 (es) 1988-04-01
CS268672B2 (en) 1990-04-11
IE58070B1 (en) 1993-06-30
KR860000299A (ko) 1986-01-27
HU202529B (en) 1991-03-28
PT80661B (en) 1987-05-04
PL145103B1 (en) 1988-08-31
AU4385785A (en) 1986-01-02
ES544344A0 (es) 1987-01-01
ES555538A0 (es) 1988-03-16
SU1433413A3 (ru) 1988-10-23
BG60305B2 (bg) 1994-07-25
AU589565B2 (en) 1989-10-19
MA20459A1 (fr) 1985-12-31
CY1750A (en) 1994-06-03
PL145105B1 (en) 1988-08-31
SU1436878A3 (ru) 1988-11-07
PL145348B1 (en) 1988-09-30
DZ799A1 (fr) 2004-09-13
NO162467B (no) 1989-09-25
KR900008566B1 (ko) 1990-11-24
BG60307B2 (en) 1994-07-25
EP0165904A3 (en) 1987-09-09
DD237510A5 (de) 1986-07-16
ES8801262A1 (es) 1987-12-16
PL145104B1 (en) 1988-08-31
IE851520L (en) 1985-12-20
ES8802049A1 (es) 1988-03-16
ES555542A0 (es) 1988-03-16
MX9203369A (es) 1992-09-01
DK277685A (da) 1985-12-21
EP0165904A2 (de) 1985-12-27
BG60262B1 (bg) 1994-03-31
NZ212483A (en) 1988-10-28
GR851487B (cs) 1985-11-25
ATE62415T1 (de) 1991-04-15
RO92583A (ro) 1987-11-30
PL254099A1 (en) 1986-09-09
BG60402B2 (bg) 1995-02-28
US4617307A (en) 1986-10-14
DK277685D0 (da) 1985-06-19
PT80661A (en) 1985-07-01
SU1436880A3 (ru) 1988-11-07
PH23390A (en) 1989-07-26
SU1436879A3 (ru) 1988-11-07
SU1482530A3 (ru) 1989-05-23
HK23494A (en) 1994-03-25
IL75546A0 (en) 1985-10-31
DK170302B1 (da) 1995-07-31
BG60262B2 (en) 1994-03-31
JPH047746B2 (cs) 1992-02-12
ZA854615B (en) 1986-02-26
ES555540A0 (es) 1987-12-16
DE3582452D1 (de) 1991-05-16
IL75546A (en) 1990-01-18
ES555541A0 (es) 1987-11-16
ES8702406A1 (es) 1987-01-01

Similar Documents

Publication Publication Date Title
CS444985A2 (en) Method of substituted imidazo-(1,5-a)pyridine derivatives production
HUT45538A (en) Process for producing quinoline derivatives and pharmaceutical compositions containing them
US4963562A (en) Nitrogen containing heterocyclic compounds

Legal Events

Date Code Title Description
MK4A Patent expired

Effective date: 20000618